Bunkerhill Health and Cleerly have entered into a strategic partnership to integrate their AI-enabled technologies for the early detection and risk assessment of coronary artery disease (CAD).
In a statement, the firms said that the collaboration will expand access to both companies’ U.S. Food and Drug Administration (FDA)-cleared software, designed to help identify at-risk patients earlier and deliver comprehensive cardiovascular care.
Bunkerhill’s FDA-cleared intracranial carotid artery calcification (ICAC) algorithm, part of its Careblocks package, detects and quantifies coronary artery calcification from nongated, noncontrast chest CTs. Cleerly’s AI-guided diagnostic system analyzes coronary computed tomography angiography (CCTA) scans to assess the risk of coronary artery disease.
The companies said that the partnership presents two-way value for their customers already using Careblocks, as the addition of Cleerly’s tool will expand the ability to assess patients who have been flagged for significant coronary calcium burden. For facilities already using Cleerly’s system, the addition of Careblocks will provide a way to identify more at-risk patients.
